Product Details:

CasNo： 827-61-2

Molecular Formula： C9H15NO2

Appearance： Off white to yellowish solid

Packing： Bottle

Throughput： 100KG/Month

Purity： 99%

Aceclidine

Free base CAS：827‑61‑2；

Aceclidine hydrochloride CAS：6109‑70‑2

Brand name：VIZZ®（1.44% ophthalmic solution，LENZ Therapeutics）

Drug class：Pupil‑selective cholinergic /muscarinic (M3) receptor partial agonist，miotic agent（缩瞳剂）FDA Access...

Official Indication（

VIZZ (aceclidine ophthalmic solution) 1.44% is indicated for the treatment of presbyopia (age‑related blurry near vision) in adult patients.

📄 Product English Description

Aceclidine is a pupil‑preferential muscarinic cholinergic partial agonist. It mainly acts on muscarinic receptors of the iris sphincter muscle with minimal stimulation to ciliary muscle. Contraction of iris sphincter produces miosis and creates a physiological pinhole effect, which extends ocular depth‑of‑focus and improves near visual acuity without significant myopic shift or deterioration of distance vision. The marketed formulation is preservative‑free single‑dose ophthalmic solution. Onset of visual improvement occurs within approximately 30 minutes post‑instillation, and therapeutic effect can sustain up to 10 hours. It is developed as a non‑surgical pharmacotherapy for adult presbyopia. Historically, aceclidine has also been used for open‑angle glaucoma via intraocular pressure‑lowering miotic action.

⚠️ Safety brief note

Most common adverse reactions include ocular irritation, conjunctival hyperemia, transient blurred vision and headache. Avoid use in patients with hypersensitivity to aceclidine. Caution for patients with risk of retinal detachment. Not recommended for children.